IPCA Laboratories Limited
IPCALAB · Pharma · NSE
₹1,583
Current Market Price
Fair Value (DCF)
₹1,070
Discount to FV
-32.4%
Updated just now
YieldIQ Score
50/100
Piotroski F-Score
7/9
Economic Moat
Narrow
Confidence
73%
ROE
14.2%
Debt/Equity
0.10
WACC
10.5%
Market Cap
₹40,161 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
23.3%
Return on capital employed
EV / EBITDA
19.8×
Enterprise multiple
Debt / EBITDA
0.4×
Leverage vs earnings
Interest Coverage
21.7×
EBIT covers interest
Current Ratio
2.76×
Short-term liquidity
Asset Turnover
0.78×
Revenue per ₹ of assets
Revenue CAGR (3Y)
15.8%
3-year revenue growth
Revenue CAGR (5Y)
12.2%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,583
Bear case
Margin of Safety —
Implied upside -142.8%
Base case
Margin of Safety -92.2%
Implied upside -48.0%
Bull case
Margin of Safety -10.5%
Implied upside -9.5%
Ratio Trends
IPCALAB · last 9 annual periods
ROE
14.2%
ROCE
23.3%
Operating Margin
—
Debt / Equity
0.10×
PE
35.6×
EV / EBITDA
19.8×
Historical Financials
IPCALAB · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹5766 Cr | ₹6207 Cr | ₹7622 Cr | ₹8940 Cr | ₹9646 Cr | +13.7% |
| EBITDA | ₹1375 Cr | ₹1052 Cr | ₹1337 Cr | ₹1614 Cr | ₹2067 Cr | +10.7% |
| EBIT | ₹1143 Cr | ₹791 Cr | ₹981 Cr | — | — | -3.8% |
| PAT | ₹884 Cr | ₹471 Cr | ₹547 Cr | ₹738 Cr | ₹1141 Cr | +6.6% |
| EPS (diluted) | ₹34.85 | ₹18.58 | ₹21.57 | — | — | -11.3% |
| CFO | ₹856 Cr | ₹806 Cr | ₹945 Cr | ₹1321 Cr | ₹1142 Cr | +7.5% |
| CapEx | ₹-479 Cr | ₹-494 Cr | ₹-411 Cr | ₹-776 Cr | ₹-656 Cr | — |
| FCF | ₹377 Cr | ₹311 Cr | ₹533 Cr | ₹546 Cr | ₹486 Cr | +6.5% |
| Total Assets | ₹7624 Cr | ₹8626 Cr | ₹11.1K Cr | ₹11.8K Cr | ₹12.4K Cr | +12.9% |
| Total Debt | ₹807 Cr | ₹1481 Cr | ₹1438 Cr | ₹1363 Cr | ₹809 Cr | +0.0% |
| Shareholders' Equity | ₹5464 Cr | ₹5842 Cr | ₹6332 Cr | ₹6948 Cr | ₹8064 Cr | +10.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
IPCALAB vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 AJANTPHARM Ajanta Pharma Limited | -137.0%-57.8% upside | 32 | Above Fair Value | 23.3% | 33.2× |
 JBCHEPHARM JBCHEPHARM | — | — | Pending | 17.1% | 46.7× |
 EMCURE EMCURE | — | — | Pending | 18.7% | — |
 GLAND GLAND | — | — | Pending | 9.9% | 27.2× |
 ABBOTINDIA ABBOTINDIA | — | — | Pending | 32.5% | 35.5× |
Click a ticker to view its fair-value analysis.
Dividend History
11 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹16.00/sh
Last payout
2025-08-05
₹2.00
Peak payout
₹4.00
Trailing yield
0.13%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. IPCA Laboratories Limited (IPCALAB.NS) trades at 1583.00 vs a model fair value of 1069.74, a gap of -32.4%. Piotroski F-score: 7/9. Moat ...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of IPCALAB →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for IPCALAB →
Compare
Head-to-head with peers
Compare IPCALAB side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse IPCALABNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.